Clinical Trial Update: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety, pharmacokinetics, and pharmacodynamics of Peglamda (peginterferon lambda-1) in healthy volunteers and a preliminary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Hepasig (ribavirin)
• Peglamda (peginterferon lambda-1)

Snippet

Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED